LadRx Highlights Patent Issued for Its LADR Technology
LadRx Corporation (OTCQB: LADX) has been granted a patent by the USPTO for its maytansinoid-based drug delivery systems. This innovation aims to enhance the delivery of chemotherapeutic agents, allowing for nearly 10 times the dosing of traditional methods. The company's lead drug candidate, Aldoxorubicin, is out-licensed to Immunity Bio, Inc., currently undergoing clinical trials for pancreatic cancer. LadRx's next-generation drugs, LADR7-10, are poised to enter IND-enabling activities and could be ready for Phase 1 trials within 18 months. The patent solidifies LadRx's IP portfolio, supporting its cancer treatment initiatives.
- Patent issued for maytansinoid-based drug delivery systems, enhancing IP portfolio.
- Potential for LADR-based drug candidates to deliver higher doses with reduced side effects.
- LADR7-10 candidates have shown strong anti-cancer activity and acceptable toxicity in pre-clinical trials.
- IND-ready candidates could advance to Phase 1 clinical trials in as little as 18 months.
- None.
“Our LADR-based drug candidates are designed to offer higher dosing of chemotherapeutic agents with lower side effects by targeting the chemotherapeutic agent to the tumor environment. Our maytansinoid drugs certainly meet that intent, with LADR-based maytansine being deliverable in animals at nearly 10-times the dosing of non-LADR maytansine. This latest patent adds to the comprehensive portfolio of intellectual property that protects our LADR-based drugs.”
Next-generation Cancer Drugs Based on LADR (“Linker Activated Drug Release”)
Our first-generation LADR-based drug candidate, Aldoxorubicin, has been out-licensed to
Forward-Looking Statements
This press release may contain certain statements relating to future results which are forward-looking statements. These statements are not historical facts, but instead represent only LadRx’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of LadRx’s control. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements; and other risks and uncertainties described in the most recent annual and quarterly reports filed by LadRx with the
About LadRx
LadRx Corporation (OTCQB: LADX) is a biopharmaceutical company with expertise in discovering and developing new therapeutics principally to treat patients with cancer. LadRx’s most recent advanced drug conjugate, aldoxorubicin, is an improved version of the widely used anti-cancer drug doxorubicin and has been out-licensed to ImmunityBio, Inc. In addition, LadRx’s drug candidate, arimoclomol, was sold to Orphazyme A/S (now Zevra Therapeutics) in exchange for milestone payments and royalties. Zevra is developing arimoclomol and is currently focused on Niemann-Pick disease Type C (NPC). LadRx Corporation’s website is www.ladrxcorp.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230327005235/en/
ladrx@longacresquare.com
Source: LadRx Corporation
FAQ
What is the significance of the patent issued to LadRx Corporation?
What are the main drug candidates being developed by LadRx Corporation?
How does LadRx's drug delivery system improve cancer treatment?
What progress has been made on Aldoxorubicin?